Literature DB >> 9918358

Positron emission tomographic studies in restless legs syndrome.

C Trenkwalder1, A S Walters, W A Hening, S Chokroverty, A Antonini, V Dhawan, D Eidelberg.   

Abstract

We studied six restless legs syndrome (RLS) patients with [F18]fluorodeoxyglucose (FDG) positron emission tomography (PET). We also studied four of these same patients with [F18]fluorodopa (FDOPA) PET. The patients' FDG and FDOPA PET scans were compared with those from age-matched healthy control subjects. No significant differences between the two groups were found for any regional blood flow values derived from the FDG scans or for any binding constants derived from the FDOPA scans. These results suggest that any abnormal resting brain metabolic activity or putative presynaptic dopaminergic defect in RLS is likely either to be so subtle that it is below the threshold for ready detection by PET or that it is located in an area of neural tissue inaccessible to the current scanner. No substantial defect is likely to involve the dopaminergic nigrostriatal axis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918358     DOI: 10.1002/1531-8257(199901)14:1<141::aid-mds1024>3.0.co;2-b

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

Review 1.  Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors:  Svenja Happe; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Restless legs syndrome.

Authors:  P Medcalf; K P Bhatia
Journal:  BMJ       Date:  2006-09-02

3.  History of the development of sleep medicine in the United States.

Authors:  John W Shepard; Daniel J Buysse; Andrew L Chesson; William C Dement; Rochelle Goldberg; Christian Guilleminault; Cameron D Harris; Conrad Iber; Emmanuel Mignot; Merrill M Mitler; Kent E Moore; Barbara A Phillips; Stuart F Quan; Richard S Rosenberg; Thomas Roth; Helmut S Schmidt; Michael H Silber; James K Walsh; David P White
Journal:  J Clin Sleep Med       Date:  2005-01-15       Impact factor: 4.062

Review 4.  Pathophysiology of restless legs syndrome: evidence for iron involvement.

Authors:  James R Connor
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

Review 5.  [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

Authors:  S Happe; W Paulus
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

6.  Genetic markers of Restless Legs Syndrome in Parkinson disease.

Authors:  Ziv Gan-Or; Roy N Alcalay; Anat Bar-Shira; Claire S Leblond; Ronald B Postuma; Shay Ben-Shachar; Cheryl Waters; Amelie Johnson; Oren Levy; Anat Mirelman; Mali Gana-Weisz; Nicolas Dupré; Jacques Montplaisir; Nir Giladi; Stanley Fahn; Lan Xiong; Patrick A Dion; Avi Orr-Urtreger; Guy A Rouleau
Journal:  Parkinsonism Relat Disord       Date:  2015-03-17       Impact factor: 4.891

7.  Restless legs syndrome: pathophysiology and treatment.

Authors:  William G Ondo
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

8.  Apomorphine in idiopathic restless legs syndrome: an exploratory study.

Authors:  G G Tribl; T Sycha; N Kotzailias; J Zeitlhofer; E Auff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

Review 9.  Sleep-related non epileptic motor disorders.

Authors:  Pasquale Montagna
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

10.  Linking restless legs syndrome with Parkinson's disease: clinical, imaging and genetic evidence.

Authors:  Tasneem Peeraully; Eng-King Tan
Journal:  Transl Neurodegener       Date:  2012-02-27       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.